DaVita Inc. reported fourth‑quarter 2025 results that exceeded analyst expectations, with adjusted earnings per share of $3.40 versus a consensus estimate of $3.19 to $3.34—a beat of $0.06 to $0.21, or 4.5% to 7.2%. The company’s revenue rose to $3.62 billion, up 9.9% year‑over‑year and 4.7% from the prior quarter, surpassing the $3.51 billion to $3.53 billion range forecast by analysts.
The earnings beat was driven by disciplined cost management and a favorable mix shift toward higher‑margin Integrated Kidney Care (IKC) services. While patient‑care costs per treatment increased 5.9% year‑over‑year, the company offset this pressure with a 4.7% rise in revenue per treatment, reflecting pricing power in its core dialysis and home‑care segments. The IKC unit, which achieved profitability in 2025 ahead of schedule, contributed significantly to the margin expansion, helping to lift adjusted operating income to $586 million for the quarter and $2.094 billion for the year.
Operating margins expanded to 15.5% in Q4 2025 from 15.2% in the prior year, a result of higher revenue per treatment and improved operational leverage. The company’s share‑buyback program, which repurchased 2.7 million shares in the quarter, further supported earnings per share by reducing diluted shares outstanding. Despite the rise in patient‑care costs, the company maintained a healthy margin profile, underscoring its ability to manage cost inflation while growing revenue.
Management raised its 2026 adjusted EPS guidance to a range of $13.60 to $15.00, up from the previous $12.50 to $13.50 range. The company also lifted its full‑year revenue outlook to $3.62 billion to $3.65 billion, reflecting confidence in continued demand for its dialysis and IKC services. CEO Javier Rodriguez emphasized that the company’s “strong platform delivered once again in 2025, providing high‑quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year.” CFO Joel Ackerman noted that the guidance “reflects a 33% growth at the midpoint” and signals “another year of strong operating performance.”
Headwinds remain, including elevated mortality rates and the expiration of enhanced premium tax credits, which could dampen treatment volumes. However, the company’s early IKC profitability and successful renegotiations with private insurers provide tailwinds that support its optimistic outlook. The combination of robust earnings, a higher guidance range, and a strategic focus on value‑based care positions DaVita to navigate short‑term challenges while pursuing long‑term growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.